We present a case series of six treatment-naive patients with clinical phenotypes compatible with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy without electrodiagnostic features of demyelination but with abnormal peripheral ultrasound findings who responded to treatment.
| INTRODUCTION
The presence of persistent conduction block or other nerve conduction study (NCS) abnormalities suggestive of (multifocal) demyelination helps to distinguish chronic motor neuropathies that respond to immune modulating treatment, such as chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), from the more common neurodegenerative lower motor neuron (LMN) disorders. According to consensus diagnostic criteria, This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.. a combination of a compatible clinical phenotype and these NCS characteristics is sufficient for a diagnosis of "probable" or "definite" CIDP or MMN, which predicts a high probability of response to treatment. 1, 2 Patients without electrodiagnostic features of demyelination are classified as having "possible" CIDP or MMN if results of additional ancillary investigations, such as brachial plexus MRI, albumino-cytological dissociation in cerebrospinal fluid, or the titre of anti-GM1 immunoglobulin (Ig) M antibodies (only for MMN), are abnormal. 3 However, treatment response rates in such cases are relatively low. Other diagnostic strategies are required to limit the number of unsuccessful trials with intravenous immunoglobulin (IVIg).
We recently showed that high-resolution ultrasound (HRUS) is a sensitive technique to identify patients with MMN and CIDP with characteristic NCS abnormalities. 4 Only a few previous reports in single patients and a retrospective chart review have noted abnormal ultrasound findings in patients without these characteristic NCS findings. [5] [6] [7] [8] Here we describe six patients suspected of an inflammatory neuropathy who lacked electrodiagnostic features of demyelination but had abnormal ultrasound findings. Response to treatment in the majority of these patients provides evidence that peripheral nerve ultrasound is a complementary diagnostic tool for evaluation of inflammatory neuropathies.
| MATERIALS AND METHODS

| Patients and routine ancillary investigations
All patients in this study presented with a clinical phenotype of a subacute or chronic symmetric or asymmetric LMN syndrome compatible with a diagnosis of CIDP or MMN. 1, 2 All were newly referred and treatment-naive patients at the neuromuscular outpatient clinic at the University Medical Centre Utrecht (UMCU) who were seen between January 2014 and January 2016. 4 They did not meet the inclusion criteria of the ongoing study to evaluate the diagnostic accuracy of HRUS in patients with inflammatory neuropathies 4 because their NCS showed no electrodiagnostic features of demyelination. 2, [9] [10] [11] They underwent extensive NCS according to a previously published standardized protocol after warming extremities in water at 37 C for 45 minutes 4, 9 and routine ancillary investigations according to consensus diagnostic guidelines. 1, 2 We used a previously published HRUS protocol of median nerves and brachial plexus trunks. 4 The physiotherapist and clinical neurophysiologist (H.F.) were blinded to the HRUS results. The treating physicians (W.L.P., L.B.) were blinded to the details of HRUS evaluations and were not allowed to read the degree of (any) enlargement.
Five patients received IVIg treatment at a cumulative dose of 2 g/kg. We evaluated treatment effects assessed at intervals of 3 to 4 weeks after initial doses using the Medical Research Council (MRC) scale, and an experienced physiotherapist independently tested for muscle strength using dynamometry of hand, pinch-and key-grip, myometry of large arm and leg muscles, and 10-m walking tests. 12 
| Standard approval of protocols and consent
The ethics committee of the UMC Utrecht approved the study protocol (14-328), and we obtained informed consent from all included participants.
| RESULTS
Five patients had a subacute or chronic onset of asymmetric weakness of the arms or symmetric weakness of the legs, and one patient had progressive sensory ataxia. Patient characteristics are presented in Table 1 , and results from ancillary investigations are presented in Table 2 (see   Table S1 ): chronic progressive asymmetric weakness compatible with -5) . Sonography results are presented in Table 3 (see Figure S1 ). Highresolution ultrasound was performed on the same day as the NCS in all but patient 6 (3-week interval We do not think that we failed to identify electrophysiological abnormalities because we used and even repeated an extensive NCS protocol that did not yield characteristics of demyelination in our patients. Our findings are in agreement with previous studies that noted sonographic enlargement in nerves without apparent demyelinating nerve conduction abnormalities. [15] [16] [17] [18] The complementary role of HRUS and NCS in the diagnostic evaluation of chronic inflammatory neuropathies mirrors that of focal neuropathies. [19] [20] [21] [22] [23] In addition, HRUS may also have prognostic value in chronic inflammatory neuropathies. [24] [25] [26] [27] [28] Magnetic resonance imaging results of the brachial plexus were abnormal in only one patient, which may suggest that the larger field of view of HRUS offers a diagnostic advantage compared to MRI. The sonographic protocol presented here takes less than 15 minutes and is time and cost efficient. Taken together, nerve ultrasound is warranted in patients in whom CIDP and MMN are suspected, both for helping to minimize overtreatment and, particularly, for early identification of treatable patients.
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